Prognosis of Patients With Acute-on-chronic Liver Failure

NCT05393453 | Unknown

• 1 other identifier: Xiangya ACLF project
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

Patients with Acute on Chronic Liver Failure (ACLF) have high short-term mortality. The use of a severity score could define the patient's prognosis. This study mainly prospectively analyze the clinical data of patients with chronic liver disease related acute liver failure admitted to the department of infectious diseases, Xiangya Hospital of Central South University, to analyze the prognosis of patients with chronic liver disease related acute on-chronic liver failure in Central South China. No additional interventions other than routine treatment will be added.

Conditions

Acute-On-Chronic Liver Failure

Outcome Measures

Primary Outcomes (5)

• Non-liver transplant mortality

  short time mortality

  15 days

• Non-liver transplant mortality

  short time mortality

  30 days

• Non-liver transplant mortality

  short time mortality

  90 days

• Non-liver transplant mortality

  long time mortality

  12 months

• Non-liver transplant mortality

  long time mortality

  36 months

Secondary Outcomes (6)

• Liver transplantation rate

  1 month

• Liver transplantation rate

  6 months

• Liver transplantation rate

  12 months

• Model for disease severity

  1 month

• Model for disease severity

  6 months

Study Arms (1)

patients with acute on chronic liver failure

All subjects will receive the currently routine treatment of liver failure and corresponding etiological treatment if needed. The researchers will collect various clinical examination results of the subjects in the process of diagnosis and treatment, including but not limited to blood routine, biochemistry, coagulation function, liver imaging, therapeutic drugs, etc. Complications and prognosis of patients will be recorded. Blood samples, urine and stool samples of all subjects will be collected after enrollment and stored for probably testing in the future. This study has no additional intervention and treatment for subjects.

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient with any cause of chronic liver disease who underwent acute liver dysfunction meets the criteria of ACLF of APASL.

You may qualify if:

• patients with evidence of chronic liver disease patients with liver failure

You may not qualify if:

• Patients who do not have chronic liver disease Patients who have hepatocellular carcinoma Patients who admitted for extrahepatic manifestations Patients who have HIV infection Patients who admitted for symptomatic control of chronic liver disease, other than acute deterioration of liver function

Sponsors & Collaborators

• Xiangya Hospital of Central South University: lead

Study Sites (1)

Xiangya Hospital

Changsha, Hunan, 410000, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

whole blood includes blood cells and serum, urine and fecal samples

MeSH Terms

Conditions

Acute-On-Chronic Liver Failure

Condition Hierarchy (Ancestors)

Liver Failure, Acute; Liver Failure; Hepatic Insufficiency; Liver Diseases; Digestive System Diseases

Central Study Contacts

Yan Huang, Professor

CONTACT

13874854142; drhyan@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 14, 2022
• First Posted: May 26, 2022
• Study Start: June 1, 2022
• Primary Completion: June 1, 2024
• Study Completion: June 1, 2025
• Last Updated: June 16, 2022

Record last verified: 2022-05

Locations

CN (1)